+357 96 030922
info@marketpublishers.com

Global Targeted PSMA Radionuclide Drug Conjugates Supply, Demand and Key Producers, 2026-2032

https://marketpublishers.com/r/GE65A8C4AA76EN.html
Date: May 2026
Pages: 107
Price: US$ 4,480.00 (Single User License)
ID: GE65A8C4AA76EN

Abstracts

The global Targeted PSMA Radionuclide Drug Conjugates market size is expected to reach $ 3466 million by 2032, rising at a market growth of 7.5% CAGR during the forecast period (2026-2032).

Targeted PSMA Radionuclide Drug Conjugates are precision radiotherapeutics designed to selectively deliver therapeutic radioisotopes to tumor tissue by targeting prostate-specific membrane antigen, or PSMA. These products are typically composed of a PSMA-targeting small molecule or ligand, a chelator, and a therapeutic radionuclide. Among current commercialized and clinical-stage products, 177Lu-labeled agents are the most mature, while alpha-emitting candidates such as 225Ac-based products are still largely in clinical development or early-stage application. This category is primarily used for the treatment of PSMA-positive advanced prostate cancer, especially metastatic castration-resistant prostate cancer, or mCRPC. Upstream segments mainly include targeting ligands and precursors, chelators, radioisotope production and purification, sterile radiopharmaceutical filling, and specialized cold-chain logistics, while downstream customers mainly consist of hospitals with nuclear medicine capabilities, cancer centers, specialty treatment networks, and radiopharmaceutical distribution systems. On a commercial-market basis, the global market in 2025 remained centered on Novartis? Pluvicto, and the industry as a whole continued to show the characteristics of limited marketed products, an active clinical pipeline, and simultaneous technical and supply-chain barriers. Because these products combine the economics of innovative oncology drugs with the operational barriers of radiopharmaceutical manufacturing, including isotope supply, dedicated facilities, quality-release requirements, and specialized distribution, gross margin is generally higher than that of conventional small-molecule drugs and standard injectables. In 2025, the gross margin of commercialized targeted PSMA radionuclide drug conjugates is estimated to

+357 96 030922
info@marketpublishers.com

be in the range of 55%-70%.

At present, the targeted PSMA radionuclide drug conjugate industry is in a stage driven by a limited number of commercialized products while accelerating into broader treatment settings. As the leading marketed products gradually move toward earlier lines of therapy, the sector is shifting from late-line clinical validation to a phase characterized by indication expansion and platform-based commercialization. This indicates that both the clinical value and commercial feasibility of the category are continuing to strengthen. Overall, market attention, capital investment, and pipeline activity are all increasing, and the industry is evolving from isolated product breakthroughs toward sustained competition centered on platform capability and indication expansion.

From the perspective of technology and product evolution, the 177Lu route is expected to remain the mainstream direction in the medium term because of its relatively mature clinical pathway, more established industrial infrastructure, and stronger commercialization foundation. At the same time, however, the industry is moving from competition around individual products to competition around platform capability. Future development is likely to focus not only on new ligand structures, combination regimens, and earlier treatment settings, but also on accelerated deployment of alpha-emitter approaches such as 225Ac in pursuit of stronger biological effects and differentiated therapeutic value. As leading companies continue to broaden their radioligand therapy portfolios, targeted PSMA drugs are likely to evolve from a single advanced prostate cancer therapy into a core component of broader radiopharmaceutical oncology platforms.

From an industrialization perspective, supply chain and manufacturing systems will be the key variables determining how quickly the industry can scale. Compared with conventional oncology drugs, targeted PSMA radionuclide drug conjugates place much higher demands on isotope supply, specialized manufacturing facilities, quality release, time-sensitive distribution, and hospital nuclear medicine capabilities. In the future, leading companies are expected to continue strengthening delivery resilience by expanding radiopharmaceutical production sites, building regional manufacturing networks, and increasing treatment-center coverage. As a result, competition will no longer be limited to the drug itself, but will increasingly become competition in integrated capabilities spanning product, manufacturing, logistics, and hospital access. In other words, companies that establish stable isotope access and strong treatment networks earlier will be better positioned in the commercialization phase.

+357 96 030922
info@marketpublishers.com

Nevertheless, the industry still faces several constraints. Stable isotope supply, the construction cycle of dedicated capacity, and the availability of specialized treatment centers remain practical bottlenecks to market expansion. In addition, patient treatment pathways usually rely on PSMA imaging selection and supporting nuclear medicine infrastructure, while reimbursement systems, hospital access, and treatment standards differ significantly across countries and regions, making global market expansion uneven. As the category moves into earlier treatment settings and addresses a broader patient population, requirements for safety management, treatment standardization, and long-term follow-up data will also continue to rise. Overall, targeted PSMA radionuclide drug conjugates offer clear long-term growth potential, but future expansion is more likely to be gradual and system-driven, supported jointly by clinical evidence, supply assurance, and healthcare infrastructure development, rather than by rapid short-term scaling.

This report studies the global Targeted PSMA Radionuclide Drug Conjugates demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Targeted PSMA Radionuclide Drug Conjugates, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Targeted PSMA Radionuclide Drug Conjugates that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Targeted PSMA Radionuclide Drug Conjugates total market, 2021-2032, (USD Million)
Global Targeted PSMA Radionuclide Drug Conjugates total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Targeted PSMA Radionuclide Drug Conjugates total market, key domestic companies, and share, (USD Million)
Global Targeted PSMA Radionuclide Drug Conjugates revenue by player, revenue and market share 2021-2026, (USD Million)
Global Targeted PSMA Radionuclide Drug Conjugates total market by Type, CAGR, 2021-2032, (USD Million)
Global Targeted PSMA Radionuclide Drug Conjugates total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global Targeted PSMA Radionuclide Drug

+357 96 030922
info@marketpublishers.com

Conjugates market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Curium, Telix Pharmaceuticals, Lantheus, Fusion Pharmaceuticals, Blue Earth Therapeutics, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Targeted PSMA Radionuclide Drug Conjugates market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Targeted PSMA Radionuclide Drug Conjugates Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Targeted PSMA Radionuclide Drug Conjugates Market, Segmentation by Type:

+357 96 030922
info@marketpublishers.com

Monotherapy Products

Combination Therapy Products

Global Targeted PSMA Radionuclide Drug Conjugates Market, Segmentation by Radionuclide Type:

Beta-emitting

Alpha-emitting

Other

Global Targeted PSMA Radionuclide Drug Conjugates Market, Segmentation by Targeting Vector Type:

Small-molecule

Antibody-based

Other

Global Targeted PSMA Radionuclide Drug Conjugates Market, Segmentation by Application:

Hospital

Clinic

Others

Companies Profiled:

Novartis

+357 96 030922
info@marketpublishers.com

Curium

Telix Pharmaceuticals

Lantheus

Fusion Pharmaceuticals

Blue Earth Therapeutics

Key Questions Answered

1. How big is the global Targeted PSMA Radionuclide Drug Conjugates market?
2. What is the demand of the global Targeted PSMA Radionuclide Drug Conjugates market?
3. What is the year over year growth of the global Targeted PSMA Radionuclide Drug Conjugates market?
4. What is the total value of the global Targeted PSMA Radionuclide Drug Conjugates market?
5. Who are the Major Players in the global Targeted PSMA Radionuclide Drug Conjugates market?
6. What are the growth factors driving the market demand?

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

3 WORLD TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES COMPANIES COMPETITIVE ANALYSIS

+357 96 030922
info@marketpublishers.com

4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)

5 MARKET ANALYSIS BY TYPE

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

10 INDUSTRY CHAIN ANALYSIS

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Targeted PSMA Radionuclide Drug Conjugates Supply, Demand and Key Producers, 2026-2032

Product link: https://marketpublishers.com/r/GE65A8C4AA76EN.html

Price: US$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GE65A8C4AA76EN.html